Xenon MRI Advances as a Cardiopulmonary Biomarker Platform at ATS 2026

Polarean, a medical imaging company, will showcase its advancements in Xenon MRI as a cardiopulmonary biomarker platform at the ATS 2026 Respiratory Innovation Summit and International Conference. The technology aims to visualize alveolar diffusion and microvascular hemodynamics, enhancing clinical trial designs and treatment response assessments. Polarean will be prominently featured with multiple presentations across the conference, showcasing a shift towards pediatric applications and improved monitoring of lung diseases. The company emphasizes the potential of Xenon MRI to provide insights into lung function that conventional methods cannot.